A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Trial Profile

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 31 Dec 2024 to 1 Jan 2025.
    • 11 Jan 2017 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
    • 19 May 2016 Planned number of patients changed from 200 to 700.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top